How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
O'FALLON, Mo., Sept. 28 /PRNewswire-FirstCall/ -- Synergetics USA, Inc.(Nasdaq: SURG) announced today that it has recorded its first orders for the second generation of its popular Photon(TM) light source. The Photon(TM) II features an advanced gas-arc lamp that offers surgeons increased wattage and a light spectrum that more closely matches the light response of the human retina.
"The additional features of the Photon(TM) II offer surgeons up to two times the apparent light levels as compared to the industry brightest Photon(TM) I," said Gregg D. Scheller, President and Chief Executive Officer of Synergetics USA, Inc. "This will allow a new generation of disposables with even smaller fibers than the first Photon(TM). Synergetics is once again excited to lead the industry in illumination technology. We hope that the Photon(TM) product line will eventually find applications not just in ophthalmology, but also in many other forms of microsurgery."
The Photon(TM) II was recently introduced to the ophthalmic community in Cannes, France at the combined meeting between the American Society of Retinal Surgeons and the European Vitreoretinal Surgeons.
About Synergetics USA, Inc.
Synergetics USA, Inc. resulted from the September 2005 combination of Valley Forge Scientific Corp. and Synergetics, Inc., bringing together their respective unique capabilities in bipolar electrosurgical generators anddesign, and manufacture of microsurgical hand instruments. Synergetics USA,Inc. designs, manufactures and markets medical devices for use primarily in ophthalmic surgery and neurosurgery and for other healthcare applications. Its products are designed and manufactured to support micro or minimally invasivesurgical procedures. In addition to its surgical devices and equipment, it designs and manufactures disposable and non-disposable supplies and accessories for use with such devices and equipment. It also manufactures and sells bipolar electrosurgical generators and other generators, based on its DualWave(TM) technology, and complementary instrumentation and disposable products for use in neurosurgery, spine surgery, pain control and in dental applications. Synergetics sells its products primarily to hospitals, clinics and surgeons in approximately 70 countries.
Some statements in this release may be "forward-looking statements" for the purposes of the Private Securities Litigation Reform Act of 1995. In somecases forward-looking statements can be identified by words such as "believe,""expect," "anticipate," "plan," "potential," "continue" or similarexpressions. Because such forward-looking statements include risks anduncertainties, actual results may differ materially from those expressed orimplied by such forward-looking statements. For example, uncertainty existswith respect to the following risks: the effects of local and nationaleconomic, credit and capital market conditions on the economy in general, andon the medical device industry in particular, and the effects of foreign exchange rates and interest rates; a significant part of our sales ofneurosurgical products comes from a single customer; if any of our singlesource suppliers were to cease providing components, we may be unable toproduce our products; the medical device industry is highly competitive, andwe may be unable to compete effectively with other companies; our futureresults are dependent, in part, upon the successful commercialization of ournew multifunctional bipolar electrosurgical generator; our products may not beaccepted in the market; if we do introduce new, commercially successfulproducts in a timely manner, our products may become obsolete over time,thereby decreasing our revenue and profitability; our operating results mayfluctuate; changes in the health care industry may require us to decrease theselling price of our products or could result in a reduction in the size ofthe market for our products, each of which could have a negative impact on ourfinancial performance; we may be unable to obtain regulatory approval tomarket our products under development; we may be unable to obtain electricalsafety approval to market our applicable products under development; ourintellectual property rights may not provide sufficient commercial protectionfor our products; we may have product liability claims, and our insurance maynot cover all claims; the loss of key personnel could harm our business; if weare unable to hire, train and retain additional sales, marketing, operations,engineering and finance personnel, our growth could be impaired; we plan toexpand our international sales and distribution operations and the success ofour international expansion is subject to significant uncertainties; we haveanti-takeover defenses that could delay or prevent an acquisition and couldadversely affect the price of our common stock; and acts of war and terrorismincidents and the effects of operating and market competition.